In Q3 2024, Foresite Capital held 5 positions worth $153.0M. They initiated 1 new position and exited 5. Their largest holding was PHVS ($81.4M). Portfolio value grew +2.8% versus the prior quarter.
Frequently asked questions
What stocks did Foresite Capital own in Q3 2024?
Foresite Capital held 5 biotech stocks in their 13F portfolio in Q3 2024. Their top positions include PHVS, KURA, SNDX, LYEL, RLAY. The full holdings table is available on BiotechEdge with position sizes, quarter-over-quarter changes, and AI analysis.
How much was Foresite Capital's portfolio worth in Q3 2024?
Foresite Capital's tracked biotech portfolio was worth $153.0M across 5 positions, with total assets under management of approximately $4B. Portfolio values are based on 13F filings with the SEC.
What did Foresite Capital buy in Q3 2024?
Foresite Capital initiated 1 new position in Q3 2024, including RLAY. They also increased 1 existing positions.
What did Foresite Capital sell in Q3 2024?
Foresite Capital fully exited 5 positions in Q3 2024, including NTRA, ACRS, CBAY, QSIAW, ASND. They also trimmed 0 existing positions.
Is Foresite Capital a biotech fund?
Data science-driven healthcare crossover fund investing from late-stage private through public equity. Uses proprietary data analytics and clinical expertise to identify asymmetric risk/reward opportunities across biotech and life sciences.
Want AI analysis, insider signals, and catalyst overlays for Foresite Capital?
View latest Foresite Capitalportfolio →